#Abu Dhabi #United Arab Emirates #Sanofi #Vaccine Innovation

Abu Dhabi's Health Ministry and Sanofi Join Forces in Vaccine Innovation

In a significant announcement at the BIO International Convention 2026, the Department of Health – Abu Dhabi (DoH) has signed a Memorandum of Understanding with biopharmaceutical leader Sanofi aimed at boosting vaccine innovation. This partnership is set to establish a Vaccine Innovation Center in Abu Dhabi, focusing on advancing various areas including AI-backed research, mRNA technology, and the clinical development and manufacturing of vaccines.

H.E. Dr. Noura Al Ghaithi, the Undersecretary of the DoH, stated, “This collaboration with Sanofi brings together AI, scientific research, and advanced manufacturing techniques within a single ecosystem. It is designed to expedite the path from discovery to application.” This forward-thinking approach reflects Abu Dhabi's commitment to creating an environment conducive to innovation, where solutions can be developed, tested, and scaled for improving health outcomes globally.

Strengthening Regional and Global Health

The partnership also aims to enhance regional and global preparedness for future public health challenges by harnessing the strengths of both organizations in vaccine innovation. Through this initiative, Abu Dhabi intends to foster local scientific talent and advance the production capabilities of next-generation vaccines. The planned center will not only serve as a hub for research but also as a leader in the region for the development and manufacturing of vaccines, directly contributing to global health security.

Baptiste de Clarens, Head of Sanofi’s Greater Gulf Vaccine Business, expressed pride in deepening the collaboration with the DoH. He stated, “Vaccine innovation today is being reshaped by artificial intelligence and advancements in mRNA research. We are excited to explore how these capabilities can be bundled together to accelerate the journey from discovery to patient delivery.”

A Comprehensive Ecosystem

The collaboration is part of the HELM cluster (Health, Endurance, Longevity, and Medicine) in Abu Dhabi, which integrates scientific research, clinical infrastructure, regulatory support, and advanced manufacturing within a cohesive ecosystem. This framework is expected to streamline processes, enhancing the overall efficiency and effectiveness of vaccine development.

Dr. Mohamed Al Ameri, Division Director of Genome and Biobank at DoH, and Laurie Gery, Global Head of Business Development Vaccines at Sanofi, also played crucial roles during the signing ceremony, which aimed to set the groundwork for future collaboration.

The initiative aligns well with Abu Dhabi’s broader vision for healthcare, promoting not just innovation in vaccine technology but also ensuring that healthcare advancements are accessible locally and globally. This comprehensive strategy intends to secure the health of communities by significantly enhancing public health responses and facilitating access to modern vaccines.

The announcement of this partnership has generated excitement across the healthcare sector, as it highlights Abu Dhabi’s growing role as a key player in the global life sciences industry. By promoting research, manufacturing, and innovation in vaccines, the DoH and Sanofi are taking significant steps toward safeguarding future public health.

As the healthcare landscape continues to evolve, initiatives like these signify a promising direction for vaccine development and public health preparedness. With collaborative efforts focused on innovation and accessibility, Abu Dhabi positions itself as a leader in transforming healthcare and improving the quality of life for communities worldwide.